Clinical Trial

Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the pharmacokinetics and safety after co-administration of L03RD1 and L03RD2 or administration of L03TD1 in healthy volunteers.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-29
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-14
Trial Details
NCT Number NCT07533539
Lead Sponsor Celltrion
Conditions Type 2 Diabetes Mellitus (T2DM)
Enrollment 48 participants
Start Date 2026-05-09
Primary Completion 2026-05-28 (estimated)
Study Completion 2026-06-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-28